Market Cap 225.95M
Revenue (ttm) 0.00
Net Income (ttm) -47.05M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio -0.68
Volume 186,700
Avg Vol 767,878
Day's Range N/A - N/A
Shares Out 63.29M
Stochastic %K 8%
Beta 0.82
Analysts Sell
Price Target $6.00

Company Profile

Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the drug research and development to create new therapies for fibrotic, cancer, and other diseases. Its lead product candidate is belapectin (GR-MD-02), a galectin-3 inhibitor, which is in Phase 2b/3 clinical trial to prevent esophageal varices in patient with non-alcoholic steatohepatitis cirrhosis; and Phase 2 clinical trial for the treatment of liver fibrosis, as well as severe skin disease, and melanoma and he...

Industry: Biotechnology
Sector: Healthcare
Phone: 678 620 3186
Address:
4960 Peachtree Industrial Boulevard, Suite 240, Norcross, United States
Indibviduate1
Indibviduate1 Aug. 18 at 8:55 AM
$GALT Is novo Nordisk a suitor after their drug was approved for f2-3 mash by the fda? They have quite a bit of cash on hand. With belapectin they would own mash f2-4. A number of suitors are likely for this drug.
0 · Reply
Indibviduate1
Indibviduate1 Aug. 18 at 8:09 AM
0 · Reply
History101
History101 Aug. 18 at 2:17 AM
$GALT accelerated approvals being done now: https://www.zerohedge.com/medical/fda-approves-therapy-rare-disease-without-randomized-trial-data
3 · Reply
Stock_Catcher
Stock_Catcher Aug. 18 at 2:04 AM
Money Monday Watchlist Pt. 11 $COEP $ENPH $CUPR $OVID $GALT Let's Have an Amazing Week 💵
0 · Reply
ThomasLD
ThomasLD Aug. 18 at 12:26 AM
$GALT Below estimation for BO > $2B came from another good source whereas Life Sci estimated $18B peak Belapectin sales in the US. But Life Sci is a very good company too. So, no one really knows where the BO price will be ended at. But keep in mind that Belapectin is a diamond 💎 without any competition for F4 patients. Very high unmet need! I have seen investors estimates $1.5b to $30B so far lol
1 · Reply
ThomasLD
ThomasLD Aug. 17 at 3:25 PM
$GALT GALT is the only player in the F4 MASH space, no competition, high unmet need, no approve drug, meet FDA primary end point, very obvious for at least conditional approval with a new voucher program. All CEOs from big pharmaceutical companies have probably been fighting with one another to get this drug ASAP especially they now know that 18 to 36 months data readout are stellar. Therefore, I think this company will like be BO very soon. Impossible to estimate the BO price. It could be $3 to $30B BO. The BO price will be higher if they wait to sell the company after approval. No need for partnerships by the end of 2025, BO instead.
1 · Reply
Jack_Capybara
Jack_Capybara Aug. 17 at 2:29 PM
$GALT Trump is pro Belapectin.
3 · Reply
Indibviduate1
Indibviduate1 Aug. 17 at 11:28 AM
$GALT does the buyout happen pre fda submission, after submission or after approval? Would a buyer want to be part of the fda approval process?
1 · Reply
Indibviduate1
Indibviduate1 Aug. 17 at 5:42 AM
$GALT @ThomasLD - Many potential opportunities here to consider and really all good ones. The unexpected can happen, but really I see Galt’s board and management wanting to hand off the whole package to a larger firm that can execute faster, more efficiently and more effectively to the benefit of all stakeholders. If you’re giving retention bonuses to keep people on board, that’s a signal. This is not a company thats going to spend another 5 or 10 years developing an enterprise. They want to handoff to a larger more capable enterprise that can quickly and effectively commercialize the product.
1 · Reply
th3_fail_k1ng
th3_fail_k1ng Aug. 17 at 3:31 AM
$GALT hey I know it's not important but this is kind of interesting did anybody else notice that the spike of selling volume that caused the price drop first thing in the morning is almost identical to the buy volume at the very end of the day? You know where they covered for 20 cents less. They penny shorted. Little bastards. And on my day off I always miss the free money smh
1 · Reply
Latest News on GALT
Galectin Therapeutics to Present at the 2025 MASH-TAG Conference

Jan 10, 2025, 8:00 AM EST - 7 months ago

Galectin Therapeutics to Present at the 2025 MASH-TAG Conference


Galectin Therapeutics to Present in Upcoming Conferences

Oct 14, 2022, 8:00 AM EDT - 3 years ago

Galectin Therapeutics to Present in Upcoming Conferences


Galectin: Ability To Potentially Target Unmet Medical Need

Jul 11, 2022, 4:16 PM EDT - 3 years ago

Galectin: Ability To Potentially Target Unmet Medical Need


Indibviduate1
Indibviduate1 Aug. 18 at 8:55 AM
$GALT Is novo Nordisk a suitor after their drug was approved for f2-3 mash by the fda? They have quite a bit of cash on hand. With belapectin they would own mash f2-4. A number of suitors are likely for this drug.
0 · Reply
Indibviduate1
Indibviduate1 Aug. 18 at 8:09 AM
0 · Reply
History101
History101 Aug. 18 at 2:17 AM
$GALT accelerated approvals being done now: https://www.zerohedge.com/medical/fda-approves-therapy-rare-disease-without-randomized-trial-data
3 · Reply
Stock_Catcher
Stock_Catcher Aug. 18 at 2:04 AM
Money Monday Watchlist Pt. 11 $COEP $ENPH $CUPR $OVID $GALT Let's Have an Amazing Week 💵
0 · Reply
ThomasLD
ThomasLD Aug. 18 at 12:26 AM
$GALT Below estimation for BO > $2B came from another good source whereas Life Sci estimated $18B peak Belapectin sales in the US. But Life Sci is a very good company too. So, no one really knows where the BO price will be ended at. But keep in mind that Belapectin is a diamond 💎 without any competition for F4 patients. Very high unmet need! I have seen investors estimates $1.5b to $30B so far lol
1 · Reply
ThomasLD
ThomasLD Aug. 17 at 3:25 PM
$GALT GALT is the only player in the F4 MASH space, no competition, high unmet need, no approve drug, meet FDA primary end point, very obvious for at least conditional approval with a new voucher program. All CEOs from big pharmaceutical companies have probably been fighting with one another to get this drug ASAP especially they now know that 18 to 36 months data readout are stellar. Therefore, I think this company will like be BO very soon. Impossible to estimate the BO price. It could be $3 to $30B BO. The BO price will be higher if they wait to sell the company after approval. No need for partnerships by the end of 2025, BO instead.
1 · Reply
Jack_Capybara
Jack_Capybara Aug. 17 at 2:29 PM
$GALT Trump is pro Belapectin.
3 · Reply
Indibviduate1
Indibviduate1 Aug. 17 at 11:28 AM
$GALT does the buyout happen pre fda submission, after submission or after approval? Would a buyer want to be part of the fda approval process?
1 · Reply
Indibviduate1
Indibviduate1 Aug. 17 at 5:42 AM
$GALT @ThomasLD - Many potential opportunities here to consider and really all good ones. The unexpected can happen, but really I see Galt’s board and management wanting to hand off the whole package to a larger firm that can execute faster, more efficiently and more effectively to the benefit of all stakeholders. If you’re giving retention bonuses to keep people on board, that’s a signal. This is not a company thats going to spend another 5 or 10 years developing an enterprise. They want to handoff to a larger more capable enterprise that can quickly and effectively commercialize the product.
1 · Reply
th3_fail_k1ng
th3_fail_k1ng Aug. 17 at 3:31 AM
$GALT hey I know it's not important but this is kind of interesting did anybody else notice that the spike of selling volume that caused the price drop first thing in the morning is almost identical to the buy volume at the very end of the day? You know where they covered for 20 cents less. They penny shorted. Little bastards. And on my day off I always miss the free money smh
1 · Reply
ThomasLD
ThomasLD Aug. 17 at 12:55 AM
$GALT We will be a next BO unexpectedly. Joe Lewis (current CEO) indicated in the past that they wanted to develop this drug to this stage, then sell the company. Richard U is getting older and he wants to cash his money out. Joe Lewis worked with Richard U in the past before both of them have joined this company.
2 · Reply
Goatedinvestor
Goatedinvestor Aug. 16 at 7:07 PM
$GALT Here's why the partnership will probably be AKRO. Belapectin has a unique MOA that can combo great with a fgf21. The problem AKRO will face when trying to expand there drug from a f2-f3 mash label to f4 is that the fda won't want to just see histologic surrogates such as “Fibrosis improvement without worsening of MASH" for f4 approval, as the liver is already compensated. Galectin knows this and understands that the long play here is a combo trial, which if successful , would essentially create a monopoly on the f4 market by 2030 (AA almost certain.) Wonder why Galectin isn't perusing a buyout right now ? It's because belapectin will 99% be the first solo drug approved in f4 cirrhosis (confirmatory trial or not ) and they know this . BP will then be forced to pay a larger multiple in a BO if they want a share in the space.
6 · Reply
AidenB
AidenB Aug. 16 at 5:35 PM
$GALT Hey all, may some please bring me up to speed on the difference of this product and MDGL and Nono"s new approval. If competing or not, and the market for each.
2 · Reply
th3_fail_k1ng
th3_fail_k1ng Aug. 16 at 5:34 PM
$GALT Biopharmaceutical company buyouts after FDA application submission but prior to approval are generally valued using a multiple of peak sales as a key benchmark. In the last 5 years, the typical acquisition multiple ranges from 4x to 7x peak sales for assets or companies at this pivotal stage. The exact multiple can vary based on factors such as therapeutic indication (oncology assets often command higher multiples), competition, the strength of clinical data, and probability of regulatory approval. Larger pharmaceutical companies may pay a premium for pipeline assets that fill strategic gaps, especially as patent cliffs or shifting market dynamics intensify the need for new revenue streams. This “peak sales rule of thumb” is one of the most widely used methods in biotech dealmaking, particularly for assets with strong Phase 3 results and visible commercial upside. Deals at this stage generally attract a higher multiple compared to earlier-stage or preclinical assets $18B or bust
2 · Reply
straightforward
straightforward Aug. 16 at 1:26 PM
$GALT Interesting announcement yesterday from Novo Nordisk. Accelerated U.S. approval for moderate to advanced liver fibrosis (stages F2 to F3 fibrosis). This will have a big impact in the F2/F3 space (more options there). Wegovy® approved in the US for the treatment of MASH The accelerated approval is based on part 1 of the ESSENCE trial, in which Wegovy® demonstrated a statistically significant and superior improvement in liver fibrosis with no worsening of steatohepatitis, as well as resolution of steatohepatitis with no worsening of liver fibrosis compared to placebo. The clinical data from ESSENCE showed that at week 72, 36.8% of people treated with Wegovy® achieved improvement in liver fibrosis with no worsening of steatohepatitis compared to 22.4% treated with placebo. 62.9% of people treated with Wegovy® achieved resolution of steatohepatitis with no worsening of liver fibrosis compared to 34.3% treated with placebo. https://ml-eu.globenewswire.com/Resource/Download/a9fe11b6-e97f-4fa1-8cb9-1ab7f20213ea
6 · Reply
Indibviduate1
Indibviduate1 Aug. 16 at 10:27 AM
$GALT 3 month chart is still impressive. Shorts like to sell it down on good news to create fear and doubt. But it was great news. The drug works.
0 · Reply
Indibviduate1
Indibviduate1 Aug. 16 at 7:10 AM
$GALT Uber bullish
0 · Reply
Indibviduate1
Indibviduate1 Aug. 16 at 5:53 AM
1 · Reply
Indibviduate1
Indibviduate1 Aug. 16 at 5:42 AM
$GALT $GALT With patents expiring in 2026-8 for the top3 selling drugs in 2024 that could leave belapectin the top slot. Because 18 billion peak sales is only for one indication in only the USA. Did the 10q sound like they were in a silent period? Lots to shout about but it was delivered very quietly. ??
0 · Reply
Indibviduate1
Indibviduate1 Aug. 16 at 5:34 AM
$GALT The drug works 18-36 months. Nothing else out there for this massive unmet need
0 · Reply
SamGantVHee
SamGantVHee Aug. 16 at 5:28 AM
$GALT 65% of volume was sells, 29% large block sells. No large block buys today. 61% dark pool, short 30% 65,000 shares left to borrow at a 61% borrow fee. Holding $3.55 was a good sign, expecting another day or two of consolidation in the lower VWAP channel. I would like to see sometime next week, a move up and consolidation in the upper VWAP channel between $3.80 - $4.15. If there is no news in the coming months, a handle consolidating in the $3.55 to $4.15 range would look really good on the 5 year chart 'chalice' (cup). If it does form, this would be a nice base to continue a strong upward move off of. If it does pull back, I want to see it hold $3.47. If that fails, then $3.41. If it falls below that, gap would fill & the longterm uptrend line (red line) would break, which is not ideal and would require further analysis of a downtrend forming.
0 · Reply
Indibviduate1
Indibviduate1 Aug. 16 at 2:46 AM
$GALT the insiders are in control. They own 86% of the company and aren’t selling. Best not to lose sight of the big picture and be confused by low volume trades selling borrowed shares as shorts fdig a deeper hole for themselves.
0 · Reply